$OKLO

DeWitte Jacob sold $1.7M of OKLO

DeWitte Jacob (Co-Founder, CEO) sold 40,000 shares of Oklo Inc. (OKLO) at $41.68 ($1.67M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DeWitte Jacob
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

The disclosed sale amount and execution price may influence short-term sentiment, but the stated 10b5-1 pre-arranged plan generally lowers the signal strength for fundamentals.

02

Market read

Traders may monitor insider selling activity, but this specific disclosure is unlikely to drive a major repricing absent additional corroborating news.

03

What to watch

The article provides only one sale event; without a pattern of prior filings, it is hard to infer whether this is routine liquidity versus a change in insider behavior.

Relevance 5/10Novelty 3/10Timing: Form 4 filed Aug 5, covering an Aug 3 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Oklo Inc., reported by its co-founder and CEO.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder and CEO DeWitte Jacob sold 40,000 shares on Aug 3 at $41.68 via a 10b5-1 plan, per Form 4 filed Aug 5.

Expected impact

Limited near-term impact expected; any effect is likely short-lived unless follow-on filings show unusual selling beyond planned activity.

Evidence & confidence

The filing discloses sale size, price, and that it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated or large insider sales can still be interpreted by some traders as confidence erosion, especially in early-stage growth names.

Key entities

  • Oklo Inc.

    Subject of the Form 4 insider sale disclosure.

  • DeWitte Jacob

    Co-Founder, CEO, and reporting insider who sold shares.

Related articles

$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

$OKLOMedAI 8/10

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.